429 related articles for article (PubMed ID: 19380028)
1. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
[TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis.
Kim WJ; Lee HL; Lee SC; Kim YT; Kim H
J Urol; 2000 Jul; 164(1):209-13. PubMed ID: 10840461
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
[TBL] [Abstract][Full Text] [Related]
5. Do smoking and polymorphisms in xenobiotic metabolizing enzymes affect the histological stage and grade of bladder tumors?
Ouerhani S; Rouissi K; Marrakchi R; Riadh Ben Slama M; Sfaxi M; Ayed M; Chebil M; Elgaaied A
Bull Cancer; 2009 May; 96(5):E23-9. PubMed ID: 19467981
[TBL] [Abstract][Full Text] [Related]
6. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls.
Nyberg F; Hou SM; Hemminki K; Lambert B; Pershagen G
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):875-83. PubMed ID: 9796632
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
8. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia.
Rouissi K; Ouerhani S; Hamrita B; Bougatef K; Marrakchi R; Cherif M; Ben Slama MR; Bouzouita M; Chebil M; Ben Ammar Elgaaied A
Pathol Oncol Res; 2011 Dec; 17(4):879-86. PubMed ID: 21647780
[TBL] [Abstract][Full Text] [Related]
9. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
McGrath M; Michaud D; De Vivo I
BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
[TBL] [Abstract][Full Text] [Related]
13. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.
Schneider J; Bernges U; Philipp M; Woitowitz HJ
Cancer Lett; 2004 May; 208(1):65-74. PubMed ID: 15105047
[TBL] [Abstract][Full Text] [Related]
14. [Associations between genetic polymorphisms of glutathione S-transferase M1 and T1, smoking and susceptibility to colorectal cancer: a case-control study].
Chen K; Jiang QT; Ma XY; Yao KY; Leng SG; Yu WP; Zhou HG
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):645-8. PubMed ID: 15777499
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer.
Kiss I; Németh A; Bogner B; Pajkos G; Orsós Z; Sándor J; Csejtey A; Faluhelyi Z; Rodler I; Ember I
Anticancer Res; 2004; 24(6):3965-70. PubMed ID: 15736440
[TBL] [Abstract][Full Text] [Related]
16. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
17. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.
Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770
[TBL] [Abstract][Full Text] [Related]
18. GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.
Zupa A; Sgambato A; Bianchino G; Improta G; Grieco V; LA Torre G; Campisi B; Traficante A; Aieta M; Cittadini A
Anticancer Res; 2009 May; 29(5):1709-14. PubMed ID: 19443391
[TBL] [Abstract][Full Text] [Related]
19. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study.
Karagas MR; Park S; Warren A; Hamilton J; Nelson HH; Mott LA; Kelsey KT
Cancer Lett; 2005 Feb; 219(1):63-9. PubMed ID: 15694665
[TBL] [Abstract][Full Text] [Related]
20. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
